289 reports of this reaction
1.2% of all ESKETAMINE HYDROCHLORIDE reports
#18 most reported adverse reaction
SUICIDE ATTEMPT is the #18 most commonly reported adverse reaction for ESKETAMINE HYDROCHLORIDE, manufactured by Janssen Pharmaceuticals Inc.. There are 289 FDA adverse event reports linking ESKETAMINE HYDROCHLORIDE to SUICIDE ATTEMPT. This represents approximately 1.2% of all 24,470 adverse event reports for this drug.
Patients taking ESKETAMINE HYDROCHLORIDE who experience suicide attempt should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SUICIDE ATTEMPT is a less commonly reported adverse event for ESKETAMINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to suicide attempt, the following adverse reactions have been reported for ESKETAMINE HYDROCHLORIDE:
The following drugs have also been linked to suicide attempt in FDA adverse event reports:
SUICIDE ATTEMPT has been reported as an adverse event in 289 FDA reports for ESKETAMINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SUICIDE ATTEMPT accounts for approximately 1.2% of all adverse event reports for ESKETAMINE HYDROCHLORIDE, making it a notable side effect.
If you experience suicide attempt while taking ESKETAMINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.